報價延遲最少15分鐘:2025/05/31 15:59 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.18 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.66/-2.72
|
|
企業價值
555.34M
|
| 資產負債 |
|
每股賬面淨值
9.04
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
263.40M
|
|
每股收益
2.18
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/31 15:59 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. |